These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1769318)

  • 1. Cefixime shows good effects on group A and group B beta-haemolytic streptococci.
    Liberto MC; Carbone M; Fera MT; Berlinghieri MC; Puccio R; Focà A; De Luca M; Casini A
    Drugs Exp Clin Res; 1991; 17(6):305-8. PubMed ID: 1769318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro antibacterial effect of a new oral cephalosporin, cefixime. Results of a multicenter study].
    Soussy CJ; Kitzis MD; Thabaut A; Chanal M; Bure A; Vergnaud M; Reynaud AE; Coulet M; Dabernat H; Muller-Serieys C
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):528-33. PubMed ID: 2508039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of cefixime: correlation index between MIC and disc diffusion test.
    Focà A; Liberto MC; Berlinghieri MC; Matera G; Puccio R; Carbone M; Fera MT
    Drugs Exp Clin Res; 1990; 16(4):175-9. PubMed ID: 2076653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefixime, a new oral cephalosporin.
    Fass RJ; Helsel VL
    Chemioterapia; 1988 Dec; 7(6):365-8. PubMed ID: 3219746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates.
    Barry AL; Jones RN
    Pediatr Infect Dis J; 1987 Oct; 6(10):954-7. PubMed ID: 3696835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of the administration of cefixime on aerobic fecal flora in children].
    Borderon JC; Bremond M; Laugier J; Despert F
    Pathol Biol (Paris); 1992 May; 40(5):440-2. PubMed ID: 1495826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens.
    Debbia EA; Marchese A; Pesce A; Saverino D; Schito GC
    J Chemother; 1992 Jun; 4(3):131-44. PubMed ID: 1517806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cefixime. Microbiologic, kinetic and clinical profile].
    Di Nola F; Arione R; Bramato C
    Minerva Med; 1991 Oct; 82(10):633-56. PubMed ID: 1745375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of cefixime, cefaclor and loracarbef against urinary pathogens.
    Hamilton-Miller JM; Brumfitt W
    Drugs Exp Clin Res; 1991; 17(10-11):517-9. PubMed ID: 1841042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alteration of bacteria induced by subinhibitory concentrations of cefixime: consequences on bactericidal activity of human polynuclear neutrophils].
    Labro MT; el Benna J; Jemni A
    Pathol Biol (Paris); 1992 May; 40(5):427-32. PubMed ID: 1495824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.
    Knapp CC; Sierra-Madero J; Washington JA
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1896-8. PubMed ID: 3245701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.
    Beekmann SE; Heilmann KP; Richter SS; García-de-Lomas J; Doern GV;
    Int J Antimicrob Agents; 2005 Feb; 25(2):148-56. PubMed ID: 15664485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sensitivity of groups A, B and C beta hemolytic streptococci to antibiotics].
    González-Lama Z; González JJ; Tejedor MT; Lupiola P
    Rev Esp Quimioter; 1999 Sep; 12(3):215-9. PubMed ID: 10878511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacologic aspects of cefixime in dogs.
    Lavy E; Ziv G; Aroch I; Glickman A
    Am J Vet Res; 1995 May; 56(5):633-8. PubMed ID: 7661460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multicenter study of the antibacterial activity of a new cephalosporin: CM 40874].
    Duval J; Soussy CJ; Deforges L; Brun Y; Coulet M; Forey F; Thabaut A; Meyran M; Acar JF; Kitzis MD
    Pathol Biol (Paris); 1984 May; 32(5):331-4. PubMed ID: 6547524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.
    Stone JW; Linong G; Andrews JM; Wise R
    J Antimicrob Chemother; 1989 Feb; 23(2):221-8. PubMed ID: 2708180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro effect of cefixime against 200 strains of Branhamella catarrhalis. Comparison with cefotaxime].
    Chardon H; Bellon O; Lagier E; Giraud E
    Presse Med; 1989 Oct; 18(32):1556-9. PubMed ID: 2530531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.
    Brogden RN; Campoli-Richards DM
    Drugs; 1989 Oct; 38(4):524-50. PubMed ID: 2684593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.